Reps. Peter Welch (D-VT) and Gregg Harper (R-MS) yesterday introduced the Closing Loopholes for Orphan Drugs Act (H.R. 2889, legislation that would limit the “orphan drug” exclusion for 340B Drug Pricing Program rural and cancer hospitals. Specifically, the legislation would allow 340B critical access hospitals, sole community providers, rural referral centers and free-standing cancer hospitals to purchase orphan drugs at discounted rates through the 340B program as long as the orphan drug is used to treat illnesses or conditions other than the rare illnesses or conditions for which the orphan drug designation was originally given.

Related News Articles

Headline
Commenting today on the Medicare Payment Advisory Commission’s draft recommendations for 2020, AHA said it supports the recommendation to provide current law…
Headline
The U.S. Supreme Court yesterday heard oral arguments in an appeal of a D.C. Circuit Court decision that the Department of Health and Human Services violated…
Headline
The Centers for Medicare…
Blog
AHA outside counsel Sean Marotta shares insight from yesterday’s oral arguments before the Supreme Court in a case about when the Department of Health and…
Perspective
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
Headline
Accountable care organizations interested in participating in the redesigned Medicare Shared Savings Program beginning July 1 must submit their notices of…